Improved insulin sensitivity after long-term treatment with AT 1 blockers is not associated with PPARγ target gene regulation

Endocrinology

Volumn 153, Issue 3, 2012, Pages 1103-1115

  Müller Fielitz, Helge ^a   Landolt, Julia ^a   Heidbreder, Marc ^a   Werth, Stefan ^a   Vogt, Florian M ^a   Jöhren, Olaf ^a   Raasch, Walter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AGOUTI RELATED PROTEIN; CANDESARTAN; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOTROPIN RELEASING FACTOR; MELANIN CONCENTRATING HORMONE; NEUROPEPTIDE Y; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN;

ABDOMINAL FAT; ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CALORIC INTAKE; CELL SIZE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; GENE CONTROL; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HEMODYNAMICS; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEADY STATE;

ADIPOCYTES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BODY WEIGHT; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; HEMODYNAMICS; HYPOTHALAMUS; INSULIN; INSULIN RESISTANCE; MALE; MODELS, BIOLOGICAL; OBESITY; PPAR GAMMA; RATS; RATS, INBRED SHR; TETRAZOLES;

EID: 84857417327     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-0183     Document Type: Article

References (72)

1. Elliott WJ, Meyer PM 2007 Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201-207 (Pubitemid 46111014)
2. Kintscher U, Foryst-Ludwig A, Unger T 2008 Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opin Ther Targets 12:1257-1263
3. Scheen AJ 2004 Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 30:487-496 (Pubitemid 40070350)
4. Scheen AJ 2004 Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30:498-505 (Pubitemid 40073639)
5. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW 2004 Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43:993-1002 (Pubitemid 38579904)
6. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thöne-Reineke C, Unger T, Kintscher U 2005 PPARγ- activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46:137-143 (Pubitemid 40946504)
7. Kintscher U, Unger T 2005 Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers. Acta Diabetol 42(Suppl 1):S26-SS32
8. Schupp M, Janke J, Clasen R, Unger T, Kintscher U 2004 Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109:2054-2057 (Pubitemid 38620211)
9. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U 2005 Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 54:3442-3452 (Pubitemid 43334334)
10. Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T, Kintscher U 2006 Regulation of peroxisome proliferator-activated receptor γ activity by losartan metabolites. Hypertension 47:586-589 (Pubitemid 43843880)
11. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF 2006 Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45:154-162 (Pubitemid 44716729)
12. Marshall TG, Lee RE, Marshall FE 2006 Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 3:1
13. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV 2005 Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112:48-53 (Pubitemid 40962568)
14. Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM 2006 Angiotensin type 1 receptor antagonists induce human in vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation. J Hypertens 24:1809-1816 (Pubitemid 44253243)
15. Larsen TM, Toubro S, Astrup A 2003 PPARγ agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 27:147-161 (Pubitemid 36255796)
16. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B 2007 Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771:1065-1081 (Pubitemid 47208546)
17. Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, Mugellini A, Preti P 2005 Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 28:209-214 (Pubitemid 40812604)
18. Sugimoto K, Qi NR, Kazdová L, Pravenec M, Ogihara T, Kurtz TW 2006 Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47:1003-1009 (Pubitemid 44297575)
19. Zanchi A, Dulloo AG, Perregaux C, Montani JP, Burnier M 2007 Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am J Physiol Endocrinol Metab 293:E91-EE95
20. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM 2006 Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARγ. Eur J Pharmacol 552:112-122 (Pubitemid 44754970)
21. Miesel A, Müller H, Thermann M, Heidbreder M, Dominiak P, Raasch W 2010 Overfeeding-induced obesity in spontaneously hypertensive rats: an animal model of the human metabolic syndrome. Ann Nutr Metab 56:127-142
22. Houseknecht KL, Baile CA, Matteri RL, Spurlock ME 1998 The biology of leptin: a review. J Anim Sci 76:1405-1420 (Pubitemid 128439681)
23. Srinivasan K, Ramarao P 2007 Animal models in type 2 diabetes research: an overview. Indian J Med Res 125:451-472 (Pubitemid 46805458)
24. Miesel A, Müller-Fielitz H, Jöhren O, Vogt FM, Raasch W 20 October 2011 Double blockade of angiotensin II (AT(1))-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats. Br J Pharmacol 10.1111/ j.1476-5381.2011.01726.x
25. Burkey BF, Dong M, Gagen K, Eckhardt M, Dragonas N, Chen W, Grosenstein P, Argentieri G, de Souza CJ 2000 Effects of pioglitazone on promoting energy storage, not expenditure, in brown adipose tissue of obese fa/fa Zucker rats: comparison to CL 316,243. Metabolism 49:1301-1308
26. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF 2001 Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50:1863-1871 (Pubitemid 33641608)
27. Hallakou S, Foufelle F, Doaré L, Kergoat M, Ferré P 1998 Pioglitazone- induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation. Diabetologia 41:963-968 (Pubitemid 28365984)
28. Larsen PJ, Jensen PB, Sorensen RV, Larsen LK, Vrang N, Wulff EM, Wassermann K 2003 Differential influences of peroxisome proliferator- activated receptors γ and -α on food intake and energy homeostasis. Diabetes 52:2249-2259 (Pubitemid 37059494)
29. Minoura H, Takeshita S, Kimura C, Hirosumi J, Takakura S, Kawamura I, Seki J, Manda T, Mutoh S 2007 Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor γagonist, FK614, ameliorates insulin resistance in Zucker fatty rats. Diabetes Obes Metab 9:369-378 (Pubitemid 46502057)
30. Raasch W, Bartels T, Schwartz C, Häuser W, Rütten H, Dominiak P 2002 Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors? J Hypertens 20:2495-2504 (Pubitemid 36026863)
31. Müller H, Schweitzer N, Jöhren O, Dominiak P, Raasch W 2007 Angiotensin II stimulates the reactivity of the pituitary-adrenal axis in leptin-resistant Zucker rats, thereby influencing the glucose utilization. Am J Physiol Endocrinol Metab 293:E802-E810 (Pubitemid 47358993)
32. Raasch W, Wittmershaus C, Dendorfer A, Voges I, Pahlke F, Dodt C, Dominiak P, Jöhren O 2006 Angiotensin II inhibition reduces stress sensitivity of hypothalamo-pituitary-adrenal axis in SHR. Endocrinology 147:3539-3546 (Pubitemid 43901145)
33. Müller-Fielitz H, Markert A, Wittmershaus C, Pahlke F, Jöhren O, Raasch W 2011 Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. Naunyn Schmiedebergs Arch Pharmacol 383:373-384
34. Hamdy O, Porramatikul S, Al-Ozairi E 2006 Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2:367-373 (Pubitemid 44734225)
35. Kohya T, Yokoshiki H, Tohse N, Kanno M, Nakaya H, Saito H, Kitabatake A 1995 Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ Res 76:892-899
36. Mukawa H, Toki Y, Miyazaki Y, Matsui H, Okumura K, Ito T 2003 Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy. Hypertens Res 26:89-95 (Pubitemid 36193103)
37. Cassano PA, Segal MR, Vokonas PS, Weiss ST 1990 Body fat distribution, blood pressure, and hypertension. A prospective cohort study of men in the normative aging study. Ann Epidemiol 1:33-48
38. Després JP 1994 Dyslipidaemia and obesity. Baillieres Clin Endocrinol Metab 8:629-660
39. Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R 2006 Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 14:336-341 (Pubitemid 46214766)
40. Seidell JC, Björntorp P, Sjöstrom L, Kvist H, Sannerstedt R 1990 Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 39:897-901 (Pubitemid 20293933)
41. Mori Y, Itoh Y, Tajima N 2007 Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 20:431-436 (Pubitemid 46441748)
42. Skurk T, Alberti-Huber C, Herder C, Hauner H 2007 Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92:1023-1033 (Pubitemid 46465679)
43. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG 2000 Central nervous system control of food intake. Nature 404:661-671 (Pubitemid 30205071)
44. Enriori PJ, Evans AE, Sinnayah P, Cowley MA 2006 Leptin resistance and obesity. Obesity (Silver Spring) 14(Suppl 5):254S-258S
45. Shimizu H, Oh-I S, Okada S, Mori M 2007 Leptin resistance and obesity. Endocr J 54:17-26 (Pubitemid 46481666)
46. He H, Yang D, Ma L, Luo Z, Ma S, Feng X, Cao T, Yan Z, Liu D, Tepel M, Zhu Z 2010 Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-Δ-dependent pathways. Hypertension 55:869-879
47. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H 2006 Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48:51-57 (Pubitemid 44297524)
48. Shimabukuro M, Tanaka H, Shimabukuro T 2007 Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25:841-848 (Pubitemid 46398879)
49. Nagel JM, Tietz AB, Göke B, Parhofer KG 2006 The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 55:1149-1154 (Pubitemid 44215933)
50. Rong X, Li Y, Ebihara K, Zhao M, Aini W, Kusakabe T, Hirata M, Miyamoto L, Murray M, Nakao K 2009 An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice. J Pharmacol Exp Ther 331:1096-1103
51. Derosa G, Fogari E, D'Angelo A, Cicero AF, Salvadeo SA, Ragonesi PD, Ferrari I, Gravina A, Fassi R, Fogari R 2007 Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 32:261-268 (Pubitemid 46699517)
52. Komiya N, Hirose H, Kawabe H, Itoh H, Saito I 2009 Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity. J Atheroscler Thromb 16:137-142
53. Makita S, Abiko A, Naganuma Y, Moriai Y, Nakamura M 2008 Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism 57:1473-1478
54. Mori Y, Itoh Y, Tajima N 2007 Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 24:146-153 (Pubitemid 46700873)
55. Nakamura T, Kawachi K, Saito Y, Saito T, Morishita K, Hoshino J, Hosoi T, Iwasaki T, Ohyama Y, Kurabayashi M 2009 Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J 50:501-512
56. Tian F, Luo R, Zhao Z, Wu Y, Ban Dj 2010 Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes 118:258-265
57. Younis F, Stern N, Limor R, Oron Y, Zangen S, Rosenthal T 2010 Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-γ activation. Metabolism 59:1200-1209
58. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, Adachi M2006 Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 55:478-488
59. Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, Silberhorn E, Böger RH 2006 Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 55:1159-1164 (Pubitemid 44219053)
60. Kamari Y, Harari A, Shaish A, Peleg E, Sharabi Y, Harats D, Grossman E 2008 Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats. Hypertens Res 31:135-140 (Pubitemid 351325625)
61. Usui I, Fujisaka S, Yamazaki K, Takano A, Murakami S, Yamazaki Y, Urakaze M, Hachiya H, Takata M, Senda S, Iwata M, Satoh A, Sasaoka T, Ak ND, Temaru R, Kobayashi M 2007 Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 77:210-214 (Pubitemid 46670421)
62. Yamada S, Ano N, Toda K, Kitaoka A, Shiono K, Inoue G, Atsuda K, Irie J 2008 Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res 31:601-605
63. Unger T 2002 The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89:3A-9A; discussion 10A
64. Moriuchi A, Yamasaki H, Shimamura M, Kita A, Kuwahara H, Fujishima K, Satoh T, Fukushima K, Fukushima T, Hayakawa T, Mizuguchi H, Nagayama Y, Abiru N, Kawasaki E, Eguchi K 2007 Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-γ activation. Biochem Biophys Res Commun 356:1024-1030 (Pubitemid 46529394)
65. Tontonoz P, Spiegelman BM 2008 Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem 77:289-312
66. Pavlatou MG, Mastorakos G, Lekakis I, Liatis S, Vamvakou G, Zoumakis E, Papassotiriou I, Rabavilas AD, Katsilambros N, Chrousos GP 2008 Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. Stress 11:62-72
67. Uresin Y, Erbas B, Ozek M, Ozkök E, Gürol AO 2004 Losartan may prevent the elevation of plasma glucose, corticosterone and catecholamine levels induced by chronic stress. J Renin Angiotensin Aldosterone Syst 5:93-96
68. Muñoz MC, Giani JF, Dominici FP, Turyn D, Toblli JE 2009 Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens 27:2409-2420
69. Horiuchi M, Mogi M, Iwai M 2006 Signaling cross talk angiotensin II receptor subtypes and insulin. Endocr J 53:1-5
70. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M 2004 Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43:1003-1010 (Pubitemid 38579905)
71. Henriksen EJ 2007 Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 293:R974-R980 (Pubitemid 47358914)
72. Lastra G, Habibi J, Whaley-Connell AT, Manrique C, Hayden MR, Rehmer J, Patel K, Ferrario C, Sowers JR 2009 Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 150:2561-2568